Form 8-K - Current report:
SEC Accession No. 0001140361-24-009377
Filing Date
2024-02-26
Accepted
2024-02-26 09:20:10
Documents
16
Period of Report
2024-02-26
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20022333_8k.htm   iXBRL 8-K 63057
2 EXHIBIT 3.1 ef20022333_ex3-1.htm EX-3.1 8893
3 EXHIBIT 3.2 ef20022333_ex3-2.htm EX-3.2 83597
  Complete submission text file 0001140361-24-009377.txt   329758

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ryzb-20240226.xsd EX-101.SCH 3865
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ryzb-20240226_lab.xml EX-101.LAB 23415
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ryzb-20240226_pre.xml EX-101.PRE 17060
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20022333_8k_htm.xml XML 4542
Mailing Address 5505 MOREHOUSE DRIVE, SUITE 300 SAN DIEGO CA 92121
Business Address 5505 MOREHOUSE DRIVE, SUITE 300 SAN DIEGO CA 92121 (619) 937-2754
RayzeBio, Inc. (Filer) CIK: 0001825367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41799 | Film No.: 24673877
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)